

## **XI. Literatur**

1. Almendingen K, Jordal O, Kierulf P, Sandstad B, Pederson JI. Effects of partially hydrogenated fish oil, partially hydrogenated soybean oil, and butter on serum lipoproteins and Lp(a) in men. *J Lipid Res* 1995; 36: 1370-1384.
2. Armstrong VW, Schuff-Werner P, Eisenhauer T et al. Heparin extracorporeal LDL precipitation (HELP): an effective apheresis procedure for lowering Lp(a) levels. *Chemistry and Physics of Lipids* 1994; 67: 315-321
3. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. *Circulation* 2002; 105: 310-305.
4. Assmann G, von Eckardstein A, Brewer HB Jr. Familial high density lipoprotein deficiency. Tangier disease. In Scriver , Beaudet, Sly, Valle(eds) *Metabolic Basis of Inherited Disease*. 7<sup>th</sup> ed. New York, McGraw-Hill, 1995, chap 65, p2053 (8<sup>th</sup> edition in press 2000)
5. Beisiegel U, Weber W, Ihrke G, Herz J, Stanley KK. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. *Nature* 1989; 341(6238):162-4.
6. Beisiegel U, Weber W, Bengtsson-Olivecrona G. Lipoprotein lipase enhances the binding of Chylomikrons to low density lipoprotein receptor-related protein. *Proc. Natl. Acad. Sci. USA* 1991; Vol. 88: 8342-8346.
7. Berg K. A new serum type system in man: the Lp system. *Acta Pathol Microbiol Scand* 1963; 59:362-382.
8. Berg A, Halle M, Franz I, Keul J. Physical activity and lipoprotein metabolism: Epidemiological evidence and clinical trials. *Eur J Med Res* 1997; 2: 259-264.
9. Berglund L, Ramakrishnan R. Lipoprotein(a) An Elusive Cardiovascular Risk Factor. *Arterioscler Thromb Vasc Biol.* 2004; 24: 2219-2226.
10. Blair SN, Kampert JW, Kohl HW, Barlow CE, Macera CA. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. *JAMA* 1996; 276: 205-21

11. Bosch T, Lennertz A, Schenzle D et al. Direct adsorption of low-density lipoprotein and lipoprotein (a) from whole blood: Results of the first clinical long-term multicenter study using DALI apheresis. *J Clin Apher* 2002; 17: 161-169.
12. Brown MS, Goldstein JL. Lipoprotein receptors in the liver. *J Clin Invest* 1983; 72: 743-749.
13. Brunner C, Lobentanz EM, Petho-Schramm A, Ernst A, Kang C, Dieplinger H, Müller HJ, Utermann G. The number of identical kringle IV repeats in apolipoprotein (a) affects its processing and secretion by HepG2 cells. *J Biol Chem* 1996; 271: 32403-32410.
14. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman LF, Prineas RJ, Friedewald W, for the Coronary Drug Project Research Group. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. *J Am Coll Cardiol* 1986; 8: 1245-55.
15. Cantin B, Gagnon F, Moorjani S, Despres JP, Lamarche B, Lupien PJ, Dagenais GR. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. *J Am Coll Cardiol* 1998; 31: 519-525.
16. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum lipoprotein Lp(a) in hyperlipemic subjects treated with nicotinic acid. *J Intern Med* 1989; 226: 271.
17. Chen SH, Habib G, Yang CY, Gu ZW, Lee BR, Weng SA, Silberman SR, Cai SJ, Deslypère JP, Roseneu M, Gotto AM, Li WH, Chan L. Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon. *Science* 1987; 238: 363-366.
18. Cremer P, Nagel D, Mann H, Labrot B, Muller-Berninger R, Elster H, Seidel D. Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men. *Atherosclerosis* 1997; 129: 221-230.
19. Daida H, LeeYJ, Kanoh T et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein (a) levels with low-density lipoprotein apheresis. Low-Density Lipoprotein Apheresis Angioplasty Restenosis Trial (L-ART) Group. *Am J Cardiol*. 1994; 15:1037-40.
20. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. *Arteriosclerosis* 1988; 8: 1-21.

21. Davoren PM, Kelly W, Gries FA, Hubinger A, Whately-Smith C, Alberti KG. Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus. *Metabolism* 1998; 47: 250-256.
22. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancina G, Manger Cats V, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D; Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Executive summary. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts. *Eur Heart J* 2003; 24: 1601-1610.
23. Derosa G, Cicero AF, Gaddi A, Mugellini A, Ciccarelli L, Fogari R. The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. *Clin Ther* 2003; 25: 1429-1439.
24. Dieplinger H, Kronenberg F. Genetics and metabolism of lipoprotein(a) and their clinical implications (Part 2). *Wien Klin Wochenschr* 1999; 111/2: 46-55.
25. Dorr AE, Gundersen K, Schneider JC, Spencer TW, Martin WB. Colestipol hydrochloride in hypercholesterolemic patients-effect on serum cholesterol and mortality. *J Chron Dis* 1978; 31: 5-14.
26. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and in women with average cholesterol levels: Results of AFCAPS/TexCAPS. *JAMA* 1998; 279: 1615-1622.
27. Eckel RH, Grundy SM, Zimmet PZ. *Lancet* 2005; 365:1415-1428.
28. Emberson JR, Whincup PH, Morris RW, Walker M. Re-assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias. *Eur Heart J* 2003; 24: 1719-1726.
29. Espeland MA, Marcovina SM, Miller V, Wood PD, Wasilauskas C, Sherwin R, Schrott H, Bush TL. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI investigators. Postmenopausal estrogen/progestin interventions. *Circulation* 1998; 97: 979-986.

30. European Atherosclerosis Society: Prevention of coronary heart disease. Scientific background and new clinical guidelines. *Nutr Metab Cardiovasc Dis* 1992; 2: 113-154.
31. European Guidelines on CVD Prevention, Third Joint European Societies Task Force on Cardiovascular Disease Prevention in Clinical Practice, *European Heart Journal* (2003) 24,1601-1610, [www.eurheartj.org](http://www.eurheartj.org)
32. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA* 2001; 285: 2486-2497.
33. Frank SL, Klisak I, Sparkes RS, Mohandas T, Tomlinson JE, McLean JW, Lawn RM, Lusis AJ The apolipoprotein(a) gene resides on human chromosome 6q26-27, in close proximity to the homologous gene for plasminogen. *Hum Genet.* 1988 Aug;79(4):352-6.
34. Fless GM, ZumMallen ME, Scanu AM. Physicochemical properties of apolipoprotein(a) and lipoprotein(a) derived from the dissociation of human plasma lipoprotein(a). *J Biol Chem* 1986; 261: 8712-8718.
35. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972; 18: 499-502.
36. Furberg CD, Vittinghoff E, Davidson M, Herrington DM, Simon JA, Wenger NK, Hulley S. Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned. *Circulation.* 2002, 105: 917-922.
37. Garry P, Collins P, Devlin JG. An open 36 month study of lipid changes with growth hormone in adults: lipid changes following replacement of growth hormone in adult acquired growth hormone deficiency. *Eur J Endocrinol* 1996; 134: 61-66.
38. Georgala S, Schulpis KH, Potouridou I, Papadogeorgaki H. Effects of isotretinoin therapy on lipoprotein(a) serum levels. *Int J Dermatol* 1997; 36: 863-864.
39. Ginsberg HN, Kris-Etherton P, Dennis B, Elmer PJ, Ershow A, Lefevre M, Pearson T, Roheim P, Ramakrishnan R, Reed R, Sreewart K, Stewart P, Phillips K, Anderson N. Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA-Study, protocol 1. *Arterioscler Thromb Vasc Biol* 1998, 18: 441-449.

40. Goldberg A, Alagona P, Capuzzi DM et al. Multiple-Dose Efficacy and Safety of an Extended-release Form of Niacin in the Management of Hyperlipidemia. *Am J Cardiol* 2000; 85:1100-1105.
41. Goldstein JL, Brown MS. The Cholesterol quartet. *Science* 2001; 292: 1310-1312.
42. Gordon D, Rifkind BM. Current concepts: high density lipoproteins – the clinical implications of recent studies. *New Engl J Med* 1989, 321: 1311-1315.
43. Gregg RE, Brewer HB jr. The role of apolipoprotein E and lipoprotein receptors in modulating the in vivo metabolism of apolipoprotein B-containing lipoproteins in humans. *Clin Chem* 1988; 34: B28-B32.
44. Hanefeld M & Temelkova-Kuktschiev. Diabetes mellitus und Dyslipoproteinämien. *Handbuch der Fettstoffwechselstörungen* 2. Auflage 2000; 239-255
45. Hansen PS, Defesche JC, Kastelein JJP, Gerdes UL et al. Phenotypic variation in patients heterozygous for familial defective apolipoprotein B(FDB) in three European countries. *Arterioscler. Thromb Vasc Biol* 17 1997 741-747.
46. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet*. 2002; 360:7-22.
47. Holme I, Urdal P, Anderssen S, Hjermann I. Exercise-induced increase in lipoprotein(a). *Atherosclerosis* 1996; 122: 97-104.
48. Jaeger BR. Evidence for maximal treatment of atherosclerosis: drastic reduction of cholesterol and fibrinogen restores vascular homeostasis. *Ther Apher* 2001; 5: 207-11
49. Jones PH, Pownell HJ, Patsch W, Herd JA, Farmer JA, Payton-Ross C, Kimball KT, Gotto AM, Morrisett JD. Effect of gemfibrozil on levels of lipoprotein(a) in type II hyperlipoproteinemic subjects. *J Lipid Res* 1996, 37, 1298-1308.
50. Julius U, Siegert G, Gromeier S. Intraindividual comparison of the impact of two selective apheresis methods (DALI and HELP) on the coagulation system. *Int J Artif Organs* 2000; 23: 199-206).
51. Kane JP, Havel RJ. Disorders of the biogenesis and secretion of lipoprotein containing the B apolipoproteins. In: Scriver CR, Beaudet AL (eds): *The metabolic basis of inherited disease*. 6<sup>th</sup> ed. McGraw-Hill New York 1989.

52. Kannel WB. An overview of the risk factors for cardiovascular disease. In: Prevention of coronary heart disease – Practical management of the risk factors. Philadelphia: WB Saunders Company 1983.
53. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. *Ann Intern Med* 1971; 74: 1-12.
54. Klett EL, Patel SB. Will the Real Cholesterol Transporter Please Stand Up. *Science* 2004; 303: 1149-1150.
55. Koenig W, Ernst E. The possible role of hemorheology in atherogenesis. *Atherosclerosis* 1992; 94: 93-107.
56. Kojima S. Low-density lipoprotein apheresis and changes in plasma components. *Therap Apher.* 2001; 5:232-238.
57. Koschinsky ML, Beisiegel U, Henne-Bruns D, Eaton DL, Lawn RM. Apolipoprotein (a) size heterogeneity is related to variable number of repeat sequences in its mRNA. *Biochemistry* 1990; 29:640-644.
58. Kronenberg F, Kronenberg MF, Kiechl S, Trenkwalder E, Santer P, Oberhollenzer F, Egger G, Utermann G, Willeit J. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. *Circulation* 1999; 100: 1154-1160.
59. Kronenberg F; Utermann G, Dieplinger H. Lipoprotein(a) in renal disease. *Am J Kidn Dis*, 27:1-25, 1996
60. Kroon AA, Aengevaeren WRM, van der Werf T, Vijen GJH, Reiber JHC, Brusckke AVG, Staelenhouf AFM. LDL Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive vs. conventional lipid lowering treatment on coronary atherosclerosis. *Circulation* 1996; 93:1826-1835.
61. Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DE. Growth hormone increases and insulin-like growth factor decreases circulating lipoprotein(a). *Eur J Endocrinol* 1997; 136: 377-381.
62. Lauterbach KW. Versorgungsmängel bei Infarktpatienten aus medizinischer und ökonomischer Sicht: Bedeutung von Leitlinien, Institut für Gesundheitsökonomie und Klinische Epidemiologie der Universität zu Köln, Dezember 1998.

63. Levy RI, Langer T. Hypolipidemic drugs and lipoprotein metabolism. *Adv Exp Med Biol* 1972; 26: 155-163.
64. Lear SA, Ignaszewski A, Linden W, Brozic A, Kiess M, Spinelli JJ, Haydn Pritchard P, Frohlich JJ. The Extensive Lifestyle Management Intervention (ELMI) following cardiac rehabilitation trial. *Eur Heart J* 2003; 24: 1920-1927.
65. Mackinnon LT, Hubinger L, Lepre F. Effects of physical activity and diet on lipoprotein(a). *Med Sci Sports Exerc* 1997; 29: 1429-1436.
66. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. *Nature* 1987; 330: 132-137.
67. März W, Wollschläger H, Klein G, Neiß A, Wehling M. Safety of LDL-Reduction with Atorvastatin versus Simvastatin in a Coronary Heart Disease Population (The TARGET TANGIBLE Trial). *Am J Cardiol* 1999; 84: 7-13.
68. Marcovina SM, Koschinsky ML. A critical evaluation of the role of Lp(a) in cardiovascular disease: can Lp(a) be useful in risk assessment? *Semin Vasc Med* 2002; 2: 335-344
69. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure and mortality: implications from a cohort of 361 662 men. *Lancet* 1986; 66: 933-936.
70. Medina J, Fernandez-Salazar LI, Garcia-Buey L, Moreno-Otero R. Approach to the Pathogenesis and Treatment of Nonalcoholic Steatohepatitis. *Diabetes Care* 2004; 27: 2057-2066.
71. Mellwig KP, Baller D, Schmidt HK et al. Myokardiale Perfusion unter H.E.L.P.-Apherese, Objektivierung durch PET. *Z Kardiol* 2003; 92: Suppl 3, III/30-III/37.
72. Milionis HJ, Winder AF, Mikhailidis DP. Lipoprotein(a) and stroke. *J Clin Pathol* 2000; 53: 487-469.
73. Morgan JM, Capuzzi DM, Guyton JR. Treatment Effect of Niaspan, a Controlled-release Niacin, in Patients With Hypercholesterolemia: A Placebo-controlled Trial. *J Cardiovasc Pharmacol Ther.* 1996; 1:195-202.
74. Murray CJ, Lopez AD. Evidence-based health policy--lessons from the Global Burden of Disease Study. *Science* 1996; 24: 740-743.

75. National Cholesterol Education Program: Detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel II). *Circulation* 1994; 89: 1329-1345.
76. Nowak-Göttl U, Junker R, Hartmeier M, Koch HG, Munchow N, Assmann G, von Eckardstein A. Increased lipoprotein(a) is an important risk factor for venous thrombembolism in childhood. *Circulation* 1999; 100: 743-748.
77. Nowak-Göttl U, Sträter R, Heinecke A, Junker R, Koch HG, Schuierer G, Eckardstein A. Lipoprotein(a) and genetic polymorphisms of clotting factor V, prothrombin and methylenetetrahydrofolate reductase are risk factors of ischemic stroke in childhood. *Blood* 1999; 94: 3678-3682.
78. Olivecrona H, Ericsson S, Berglund L, Angelin B. Increased concentrations of serum lipoprotein(a) in response to growth hormone treatment. *BMJ* 1993; 306: 1726-1727.
79. Olivecrona G, Beisiegel U. Lipidbinding of Apo CII is required for stimulation of lipoprotein lipase activity. *Arteriosclero Thromb Vasc Biol.* 1997 Aug; 17(8): 1545-1549.
80. O'Driscoll G, Green D, Taylor R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. *Circulation* 1997; 95: 1126-1131.
81. Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, McLanahan SM, Kirkeeide RL, Brand RJ, Gould KL. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. *Lancet* 1990; 336: 129-33.
82. Oscarsson J, Lundstam UK, Gustaffson B, Wilton P, Edén S, Wiklund O. Recombinant human insulin-like growth factor-1 decreases serum lipoprotein(a) concentrations in normal adult men. *Clin Endocrinol* 1995; 42: 673-676.
83. Parhofer KG, Demant T, Ritter MM, Geiss HC, Donner M, Schwandt P. Lipoprotein(a) metabolism estimated by nonsteady-state kinetics. *Lipids* 1999; 34: 325-335
84. Paasilta M, Kervinen K, Linnaluoto M, Kesäniemi YA. Alcohol withdrawal-induced change in lipoprotein(a). Association with the growth hormone/insulin like growth factor-I (IGF-I)/IGF-binding protein-1 (IGFBP-1) axis. *Arterioscler Thromb Vasc Biol* 1998; 18: 650-654.
85. Perombelon YFN, Soutar AK, Knight BL, Variation in lipoprotein (a) concentration associated with different apolipoprotein(a) alleles. *J Clin Invest.* 93:1481-1492,1994



86. Peterson J, Bihain BE, Bengtsson-Olivecrona G, Deckelbaum RJ, Carpentier YA, Olivecrona T. Fatty acid control of lipoprotein lipase: a link between energy metabolism and lipid transport. *Proc Natl Acad Sci USA* 1990; 87: 909-913.
87. Pignone MP, Phillips CJ, Atkins D, Teutsch SM, Mulrow CD, Lohr KN. Screening and treating adults for lipid disorders. *Am J Prev Med* 2001; 20: 77-89.
88. Pitsavos C, Panagiotakos DB, Chrysohoou C, Kokkinos PF, Skoumas J, Papaioannou I, Stefanadis C, Toutouzas P. The effect of the combination of Mediterranean diet and leisure time physical activity on the risk of developing acute coronary syndromes, in hypertensive subjects. *J Hum Hypertens*. 2002; 16: 517-524.
89. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. *Lancet* 1993; 342: 697-699.
90. Pokrovsky SN, Adamova IY, Afanasieva OI et al. Immunosorbent for selective removal of lipoprotein(a) from human plasma: in vitro study. *Artif Organs* 1991; 15:136-146.
91. Pullinger CR, Kane JP & Malloy MJ. Primary hypercholesterolemia: genetic causes and treatment of five monogenic disorders. *Expert Review of Anticancer Therapy* 2003 1(1),107–119
92. Ramharack R, Spahr MA, Sekerke CS, Stanfield RL, Bousley RF, Lee HT, Krause BK. CI-1011 lowers lipoprotein(a) and plasma cholesterol in chow-fed cynomolgus monkeys. *Atherosclerosis* 1998; 136: 79-87.
93. Reblin T, Meyer N, Labeur C, Henne-Bruns D, Beisiegel U. Extraction of lipoprotein(a), apo B, and apoE from fresh human arterial wall and atherosclerotic plaques. *Atherosclerosis* 1995; 113: 179-188.
94. Rimm EB, Giovannucci EL, Willet WC, Colditz GA, Ascherio A, Rosner B, Stampfer MJ. Prospective study on alcohol consumption and risk of coronary disease in men. *Lancet* 1991; 338: 464-468.
95. Rosén T, Bengtsson BÅ. Premature mortality due to cardiovascular disease in hypopituitarism. *Lancet* 1990; 336: 285-288.
96. Sacks FM, Pfeiffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.

- Cholesterol and Recurrent Events Trial investigators. *N Engl J Med* 1996; 335: 1001-1009.
97. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994; 344: 1383-1389.
98. Scottish Intercollegiate Guidelines Network 1999. Lipids and the primary prevention of coronary heart disease. A national clinical guideline, September 1999, <http://www.show.scot.nhs/signguidelines/fulltext/40/index.htm>
99. Schwabe U, Paffrath D. *Arzneiverordnungs-Report 1999*, Kap. 32. Springer-Verlag: 432-443.
100. Schwandt P, Geiss HC, Ritter MM, Ublacker C, Parhofer KG, Otto C, Laubach E, Donner MG, Haas GM, Richter WO. The prevention education program (PEP). A prospective study of the efficacy of family-oriented life style modification in the reduction of cardiovascular risk and disease: design and baseline data. *J Clin Epidemiol* 1999; 52: 791-800.
101. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. *N Engl J Med* 1995; 333: 1301-1307.
102. Shinozaki K, Kambajyshi J, Kawasaki T, Uemura Y, Sakon M, Shiba E, Shibuya T, Nakamura T, Mori T. The long-term effect of eicosapentaenoic acid on serum levels of lipoprotein(a) and lipids in patients with vascular disease. *J Atheroscler Thromb* 1996; 2: 107-109.
103. Shoulders CC, Jones EL, Naoumova RP. Genetics of familial combined hyperlipidemia and risk of coronary heart disease. *Hum Mol Genet.* 2004 Apr 1; Spec No 1: R 149-160.
104. Smelt AH, de Beer F. Apolipoprotein E and familial dysbetalipoproteinemia: clinical, biochemical, and genetic aspects. *Semin Vasc Med* 2004 Aug; (4)3:249-257.
105. Steinhagen-Thiessen E, Borchelt M. Morbidität, Medikation und Funktionalität im Alter. In: *Die Berliner Altersstudie (BASE)*. Mayer KU, Baltes PB (Hrsg). 151-183.

106. Sträter R, Becker S, von Eckardstein A, Heinecke A, Gutsche S, Junker R, Kurnik K, Schobess R, Nowak-Göttl U. Prospective assessment of risk factors for recurrent stroke during childhood: a 5-year follow-up study. *Lancet* 2002; 360:1540-1545.
107. Straube R, Kingreen H. Lipoprotein(a) immunapheresis in the treatment of familial lipoprotein(a) hyperlipoproteinemia in a patient with coronary heart disease. *Ther.Apher.* 1998; 2: 243-244
108. Steinmetz A, Barbaras R, Ghalim N, Clavey V, Fruchart JC, Ailhaud G. Human apolipoprotein A IV binds to apolipoprotein A-I/A-II receptor sites and promotes cholesterol efflux from adipose cells. *J Biol Chem* 1990; 265: 7859-7863.
109. Tanaka K, Hayashi K, Shingu T, Kuga Y, Okura Y, Yasunobu, Y, Ohtani H, Momura S, Kurushima H, Saeki M, Kambe M, Kajiyama G. Pentaerythritol tetranicotinate (niceritrol) decreases plasma lipoprotein(a) levels. *Metabolism* 1997; 46: 355-358.
110. The International Task Force for Prevention of Coronary Heart Disease. In cooperation with the International Atherosclerosis Society. Coronary heart disease: Reducing the risk. The scientific background for primary and secondary prevention of coronary heart disease. A worldwide view. *Nutr Metab Cardiovasc Dis* 1998; 8: 205–73:
111. Thiery J, Seidel D. Safety and effectiveness of long-term LDL-apheresis in patients at high risk. *Curr Opin Lipidol* 1998; 9: 521-526
112. Thiery J, Ivandic B, Bahlmann G, Walli AK, Seidel D. Hyperlipoprotein(a)emia in nephrotic Syndrome. *Eur J Clin Invest.* 26:316-321, 1996
113. Thomas HP, Vogt A, Wilund KR, Schliesser C, Steinhagen-Thiessen E, Kassner U. Autosomal recessive Hypercholesterolemia in three sisters with phenotypic homozygous familial hypercholesterolemia: diagnosis and therapeutic procedures. *Ther Apher Dial* 2004 Aug; 8(4): 275-80.
114. Thomas HP. Lipoprotein(a): Aspekte der Pathophysiologie, Epidemiologie und Therapie. *Z Kardiol* 2003; 92: Suppl 3.
115. Thomas HP, Steinhagen-Thiessen E. Indications and contra-indications for statin treatment (primary and secondary prevention of hypercholesterolemia). In: Schmitz G. Torzewski (Hrsg). *Milestones in drug therapy.* 2002; Birkhäuser Verlag, Basel
116. Wood D, De Backer G, Faergeman O, Graham I., Mancina G, Pyörälä K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task

- Force of European and other Societies on coronary prevention. *Eur Heart J* 1998; 19: 1434-1503.
117. Thiery J, Armstrong VW, Schleef J, Creutzfeld C, Creutzfeld W, Seidel D. Serum lipoprotein(a) concentrations are not influenced by an HMG CoA reductase inhibitor. *Klin Wochenschr* 1988; 66: 462-463.
118. Tholstrup T, Marckmann P, Vessby B, Sandström B. Effects of fat high individuell saturated fatty acids on plasma lipoprotein(a) in young healthy men. *J Lipid Res* 1995; 36: 1447-1452.
119. Thompson GR, Maher VMG, Matthews S, Kitano Y, Neuwirth C, Shortt MB, Davies G, Rees A, Mir A, Prescott RJ et al. Familial hypercholesterolaemia regression study: a randomized trial of low-density-lipoprotein apheresis. *Lancet* 1995; 119: 99-106.
120. Tuck CH, Holleran S, Berglund L. Hormonal regulation of lipoprotein(a) levels: effects of estrogen replacement therapy on lipoprotein(a) and acute phase reactants in postmenopausal women. *Arterioscler Thromb Vasc Biol* 1997; 17: 1822-1829.
121. Tyroler HA. Review of lipid-lowering trials in relation to observational epidemiologic studies. *Circulation* 1987; 76: 515-522.
122. Ullrich H, Lackner K, Schmitz G. Lipoprotein(a)-apheresis in the Secondary Prevention of Coronary Heart Disease. *Transfus. Sci.* 1996; 17: 511-517.
123. Utermann G. The mysteries of lipoprotein (a). *Science* 1989; 246: 904-910.
124. Vance DE, Vance JE. *Biochemistry of lipids, lipoproteins and membranes*. New Comprehensive Biochemistry 20 Elsevier, Amsterdam.
125. Velazquez EM, Mendoza SG, Wang P, Glueck CJ. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. *Metabolism* 1997; 46: 454-457.
126. Vessby B, Kostner G, Lithell H, Thomis J. Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a). A dose response study of the effects of cholestyramine in hypercholesterolaemia. *Atherosclerosis* 1982; 44: 61-71.
127. Völler HH, Hahmann H, Gohlke G, Klein B, Rombeck S, Binting SN, Willich S. Auswirkung stationärer Rehabilitation auf kardiovaskuläre Risikofaktoren bei Patienten mit koronarer Herzerkrankung. *DMW* 1999; 12: 817-823.

128. Völler H, Klein G, Gohlke H, Hahmann H, Dovifat C, Binting S, Willich SN für die PIN-Studiengruppe. Sekundärprävention Koronarkranker nach stationärer Rehabilitation. *DMW* 1999; 124: 817-823.
129. van Wissen S, Smilde TJ, Trip MD, de Boo T, Kastelein JJ, Stalenhoef AF. Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia. *Heart* 2003; 89: 893-896.
130. von Depka M, Nowak-Göttl U, Eisert R, Dieterich C, Barthels M, Scharrer I, Ganser A, Ehrenforth S. Increased lipoprotein (a) levels as an important risk factor for venous thrombembolism. *Blood* 2000; 96: 3364-3368.
131. von Eckardstein A, Schulte H, Cullen P, Assmann G. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. *J Am Coll Cardiol.* 2001; 37: 434-439.
132. Weisgraber KH, Rall SC jr, Mahley RW. Human E apoprotein heterogeneity. Cysteine arginine interchanges in the amino acid sequence of the apo E isoforms. *J Biol Chem* 1981; 256: 9077-9083.
133. Wierzbicki A.S. FIELDS of dreams, fields of tears: a perspective on the fibrate trials *Int J Clin Pract*; 2006, 60, 4, 442-449.
134. White AL, Lanford RE. Biosynthesis and metabolism of lipoprotein(a). *Curr Opin Lipidol* 1995; 6: 136-145.
135. Wood D, De Backer G, Faergeman O, Graham I, Mancina G, Pyörälä K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. *Eur Heart J* 1998; 19: 1434-1503.
136. Young SG. Recent progress in understanding apolipoprotein B. *Circulation* 1990; 82: 1574-1594.
137. Zannis VI, Breslow JL. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. *Biochemistry* 1981; 20: 1033-1041.
138. Zannis VI, Breslow JL, Utermann G; Mahley RW, Weisgräber KH, Havel RJ, Goldstein JL, Brown MS, Schönfeld G, Hazzard WR, Blum C. *J. Lipid Res.* 1982; 23: 911-914

